Volume 6.07 | Feb 27

Mammary Cell News 6.07 February 27, 2014
Mammary Cell News
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  ESC & iPSC News on Twitter
 
TOP STORY
The Breast Cancer Oncogene EMSY Represses Transcription of Antimetastatic MicroRNA miR-31
Researchers report that EMSY acts as an oncogene, causing the transformation of cells in vitro and potentiating tumor formation and metastatic features in vivo. [Mol Cell] Full Article | Graphical Abstract
FREE ALDEFLUOR™ Protocol Optimization Resource Pack – Get Yours
 
PUBLICATIONS (Ranked by impact factor of the journal)
LABORATORY RESEARCH

Estrogen Controls the Survival of BRCA1-Deficient Cells via a PI3K-NRF2-Regulated Pathway
Investigators showed that estrogen (E2) increases the expression of NRF2-dependent antioxidant genes in various E2-responsive cell types. [Proc Natl Acad Sci USA] Abstract

Estrogen Receptor Beta as a Novel Target of Androgen Receptor Action in Breast Cancer Cell Lines
Researchers demonstrated that mibolerone, a synthetic androgen ligand, up-regulates estrogen receptor (ER)-beta mRNA and protein levels in ER-positive breast cancer cells. [Breast Cancer Res] Abstract | Full Article

Eribulin Mesilate Suppresses Experimental Metastasis of Breast Cancer Cells by Reversing Phenotype from Epithelial-Mesenchymal Transition to Mesenchymal-Epithelial Transition States
Treatment of triple negative breast cancer cells with eribulin in vitro led to morphological changes consistent with transition from a mesenchymal to an epithelial phenotype. [Br J Cancer] Full Article

Conditional Over-Expression of Liver Receptor Homolog-1 in Female Mouse Mammary Epithelium Results in Altered Mammary Morphogenesis via the Induction of Transforming Growth Factor-ß
Researchers used siRNA knockdown strategies in order to deplete liver receptor homolog-1 (LRH-1) in breast cancer cells and followed with microarray analysis to identify LRH-1 dependent mechanisms. They identified key genes involved in TGF-ß signaling to be highly responsive to LRH-1 knockdown. [Endocrinology] Abstract

Wnt Modulates MCL1 to Control Cell Survival in Triple Negative Breast Cancer
Researchers directed their focus on identifying the WNT ligand and its underlying mechanism in triple negative breast cancer cells. [BMC Cancer] Abstract | Full Article

Targeting Met and Notch in the Lfng-Deficient, Met-Amplified Triple-Negative Breast Cancer
To examine roles of Met and Notch in triple negative breast cancer cells, scientists established two cell lines that harbor Met amplification as well as Lfng deletion, and possess features of basal and claudin-low breast cancer subtypes. [Cancer Biol Ther] Abstract

Histone Demethylase RBP2 Is Critical for Breast Cancer Progression and Metastasis
By using both human breast cancer cells and genetically engineered mice, researchers demonstrated that RBP2 is critical for breast cancer metastasis to the lung in multiple in vivo, models. [Cell Rep]
Full Article | Graphical Abstract

CLINICAL RESEARCH

Optimum Duration of Neoadjuvant Letrozole to Permit Breast Conserving Surgery
The aim of this multicenter, prospective, longitudinal Phase IV study was to establish the optimal duration of neoadjuvant letrozole that would allow breast conservation surgery in patients with early breast cancer who were initially unsuitable. [Breast Cancer Res Treat] Abstract

Disseminated Tumor Cells as a Monitoring Tool for Adjuvant Therapy in Patients with Primary Breast Cancer
Investigators aimed to assess whether adjuvant systemic therapy has the ability to eradicate disseminated tumor cells (DTC) and to determine the clinical impact of DTC-persistence. [Breast Cancer Res Treat] Abstract

Culture and Characterize Mouse Mammary Epithelial Progenitors with Serum-Free EpiCult-B (Mouse) - Free Protocols
 
REVIEWS
Nutrient Transport in the Mammary Gland: Calcium, Trace Minerals and Water Soluble Vitamins
The authors focus on transport mechanisms that contribute to the secretion of calcium, trace minerals and water soluble vitamins into milk with particular focus on the role of transporters of the SLC series as well as calcium transport proteins. A deeper understanding of the physiology and pathophysiology of these transporters will be of great value for drug discovery and treatment of breast diseases. [J Mammary Gland Biol Neoplasia] Abstract

Visit our reviews page to see a complete list of reviews in the mammary cell research field.

Cell Line Development Asia 2014
 
INDUSTRY NEWS
Calithera Biosciences Initiates Three Phase I Trials with First-in-Class Glutaminase Inhibitor CB-839 in Patients with Advanced Solid and Hematological Cancers
Calithera Biosciences, Inc. announced the commencement of patient dosing in its first Phase 1 study of CB-839 in patients with advanced solid tumors. CB-839 is a potent, selective, orally bioavailable inhibitor of glutaminase that interferes with tumor metabolism and blocks cancer cell growth and survival. [Calithera Biosciences, Inc.] Press Release

Eisai Announces Initiation of a Phase III Trial of Eribulin Mesylate Injection Versus Weekly Paclitaxel in First and Second Lines of Metastatic Breast Cancer
Eisai Inc. announced the start of a large, randomized Phase III trial to compare the efficacy, safety and tolerability of eribulin mesylate to standard weekly paclitaxel as a first- or second- line treatment for HER2-negative locally recurrent or metastatic breast cancer. [PR Newswire Association LLC] Press Release

From our sponsor: Pluripotent cell isolation for regenerative medicine. Request a free wallchart from Nature.
 
POLICY NEWS
National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)
 
EVENTS
NEW Anti-Cancer Therapeutics: From Research to Trials to Treatment
May 14, 2014
London, United Kingdom

Visit our events page to see a complete list of events in the mammary cell community.
 
JOB OPPORTUNITIES
NEW Higher Scientific Officer – Breast Development (Institute of Cancer Research)

Postdoctoral Fellow – Process of Mammary Differentiation (University of British Columbia)

PhD Position – Grading CIN in the Mammary Gland (European Molecular Biology Laboratory)

Studentship – Microtubules and End-Binding Proteins in Epithelial Remodeling and Breast Cancer Invasion (University of East Anglia)

Postdoctoral Fellow – Mechanisms that Contribute to Metastases of Breast Cancer Cells (Mount Sinai Medical Center/Icahn School of Medicine at Mount Sinai)

Postdoctoral Fellow – Hodgkin Lymphoma and Breast Cancer (Hackensack University Medical Center)

Postdoctoral Position – Functions of Epigenetic Enzymes in Breast Cancer (University of Wisconsin-Madison)

Postdoctoral Position – Breast Cancer Metastasis (Weizmann Institute of Science)

Postdoctoral Fellow – Morphogenetic Signaling Pathways in Development and Disease (University of Rochester Medical Center)

Postdoctoral Research Fellow (Brigham & Women’s Hospital and Harvard Medical School)

Postdoctoral Position – Stem Cells and Cancer (Brigham & Women’s Hospital – Harvard Medical School)

Research Technologist – Pluripotent Stem Cells (STEMCELL Technologies Inc.)

Research Technologist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – PSC Biology and Bioengineering (STEMCELL Technologies Inc.)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
 

Have we missed an important article or publication in Mammary Cell News? Click here to submit!

Comments or Suggestions? Submit your feedback here.
Learn more about Mammary Cell News: Archives | Events | Contact Us